Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 4, 2010 Brian Orelli	A Drugless Drugmaker IPO! Biotech investors embrace risk ... sort of. The most exciting thing about Ironwood's IPO? The company doesn't have any drugs on the market.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool August 13, 2007 Andrew R. Vaino	Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow.
The Motley Fool August 23, 2010 Brian Orelli	No Way to Jazz Up This Result Jazz Pharmaceuticals investors went from ecstatic to devastated in less than a week.
The Motley Fool August 18, 2010 Brian Orelli	No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals
The Motley Fool December 31, 2010 Brian Orelli	3 Biotech 2010 IPOs Worthy of a Look These IPOs are worth a spot on your watchlist.
The Motley Fool August 10, 2010 Brian Orelli	Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option.
The Motley Fool May 18, 2011 Sean Williams	10 Mid Caps to Rule Them All The future of Jazz Pharmaceuticals' narcolepsy drug is so bright you may actually sleep better at night.
The Motley Fool June 30, 2011 Brian Orelli	2 Backdoor Biotech IPOs to Watch Just don't buy yet.
The Motley Fool December 27, 2010 Brian Orelli	FDA Kicks Dust on Alimera's Fairy Tale Eight months after its IPO, Alimera gets hammered.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool March 4, 2004 Brian Gorman	Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool March 8, 2006 Tim Hanson	IPOs' Dirty Little Secret There's optimism around the market's newest offerings, but is it warranted? Many IPOs just flat out fail to perform over long periods of time. Investors -- never buy the hype and never overpay.
The Motley Fool February 28, 2011 Brian Orelli	6 Health-Care IPOs; 3 Worth Watching The health-care-company IPO window has cranked wide open over the past few weeks. But investors haven't been all that eager to catch every company jumping through that window.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool October 11, 2007 Billy Fisher	An IPO That Hit the Bull's-Eye Sirtris Pharmaceuticals presents promising drug data and is turning out to be one of the top-performing IPOs in the biotech/pharmaceutical field in 2007.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool August 10, 2010 Brian Orelli	When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow.
The Motley Fool September 7, 2010 Luke Timmerman	ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C.
The Motley Fool April 27, 2011 Brian D. Pacampara	Jazz Pharmaceuticals Shares Plunged then Recovered: What You Need to Know Shares of drug maker Jazz Pharmaceuticals suddenly plummeted 30% this morning only to quickly recover the majority of that loss.
The Motley Fool August 11, 2009 Brian Orelli	A Drug Stock IPO! Finally! Today's offering, Cumberland Pharmaceuticals is in a special breed of small drugmakers: it's actually profitable.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool April 5, 2011 Frank Vinluan	Tranzyme Pharma's Public Offering Raises $48M, but IPO Has Little Bounce Tranzyme Pharma likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool January 25, 2005 Charly Travers	Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs.
The Motley Fool May 30, 2008 Brian Orelli	WuXi Woos Pharma Pharmaceutical outsourcing specialist WuXi PharmaTech proves that outsourcing to China isn't dead yet and neither are Chinese companies moving stateside.
The Motley Fool March 14, 2008 Brian Orelli	No Slowdown for China's WuXi Chinese drug researcher and manufacturer WuXi signs more drug development deals and buys a U.S. manufacturing services company.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
The Motley Fool July 29, 2009 Selena Maranjian	Should You Be an Instant IPO Investor? Not all IPOs perform spectacularly. If you do decide to invest in them, be choosy. Yes, many will be unspectacular performers. But some will shine.
The Motley Fool January 28, 2011 Brian Orelli	Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff.
The Motley Fool October 11, 2010 Brian Orelli	FDA Rejection, but Still Jazzed Up Sometimes, biotechs are like that.
The Motley Fool August 1, 2008 Brian Orelli	Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit.
The Motley Fool May 3, 2011 Dan Caplinger	Be a Smarter IPO Investor Some IPOs soar and others bomb. Be aware of the traps.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
BusinessWeek June 12, 2006 Catherine Arnst	Going From The Lab To Limbo The FDA has been delaying decisions on applications, and drugmakers are fuming.
Entrepreneur January 2004 David Worrell	Waiting in the Wings Is the IPO market poised for a better performance in the coming year?
The Motley Fool August 27, 2007 S.J. Caplan	Scouting the Latest IPOs An investor's roundup of new-issue hits, misses, and no-shows: Abraxas Energy Partners... McLeod USA... ZARS Pharma... Adnexus Therapeutics... Orion Energy Systems...
The Motley Fool September 25, 2007 Billy Fisher	Bristol-Myers Buys In to Biologics Looking to advance its biologics strategy, Bristol-Myers Squibb announces it will acquire Adnexus Therapeutics, a privately held developer of biologics.
Financial Planning March 1, 2012 Donald Jay Korn	First Impressions Not every planner will want to delve deeply into individual IPOs. A simpler approach to IPOs is simply to wait and see. "Waiting is prudent," Krapfel says. "You'll want to see an economic moat to keep out competitors, and you'd like to see profits."
The Motley Fool May 21, 2004	IPO Lock-Up Period Understand how initial public offerings work before you invest in any.
Entrepreneur October 2002 Jennifer Pellet	Public Opinion Becoming synonymous with inflated valuations and dotcom disasters hasn't done much for IPOs' reputation. How long before we can start to talk about going public again without snickering?
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.